



1624

PATENT  
Customer No. 22,852  
Attorney Docket No. 05281.0009

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
)  
PFLEIDERER, Wolfgang ) Group Art Unit: 1624  
)  
Appl. No.: 10/070,976 ) Examiner: Richard Raymond  
)  
Filed: March 13, 2002 )  
)  
For: N-SUBSTITUTED 4- )  
AMINOPTERIDINES, A PROCESS )  
FOR THEIR PREPARATION AND )  
THEIR USE AS )  
PHARMACEUTICALS )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL RESPONSE**


In reply to the Official Action mailed May 12, 2004, Applicants enclose a certified copy of the English translation of German Priority Application No. 199 44 767.5.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: August 12, 2004

By:   
Anthony C. Tridico  
Reg. No. 45,958

UNITED STATES PATENT AND TRADEMARK OFFICE

I, Susan ANTHONY BA, ACIS,  
Director of RWS Group Ltd, of Europa House, Marsham Way, Gerrards Cross,  
Buckinghamshire, England declare;

1. That I am a citizen of the United Kingdom of Great Britain and Northern Ireland.
2. That the translator responsible for the attached translation is well acquainted with the German and English languages.
3. That the attached is, to the best of RWS Group Ltd knowledge and belief, a true translation into the English language of the accompanying copy of the specification filed with the application for a patent in Germany on 17 September 1999 under the number 199 44 767.5 and the official certificate attached hereto.
4. That I believe that all statements made herein of my own knowledge are true and that all statements made on information and belief are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the patent application in the United States of America or any patent issuing thereon.



For and on behalf of RWS Group Ltd

The 5th day of August 2004

**FEDERAL REPUBLIC OF GERMANY**

**[Eagle crest]**

**Priority Certificate  
for the filing of a Patent Application**

**File Reference:** 199 44 767.5

**Filing date:** 17 September 1999

**Applicant/Proprietor:** Vasopharm Biotech GmbH & Co KG, Würzburg/DE

**Title:** N-Substituted 4-aminopteridines, a process for their preparation and their use as pharmaceuticals

**IPC:** C 07 D, A 61 K

**The attached documents are a correct and accurate reproduction of the original submission for this Application.**

Munich, 22 August 2000

**German Patent and Trademark Office**

**The President**

[Seal of the German Patent  
and Trademark Office]

pp

[signature]

Waasmaier


Vasopharm Biotech GmbH & Co. KG

Attorney reference: va19901a.de

N-Substituted 4-aminopteridines, a process for their preparation and their use as pharmaceuticals

5 Description

The present invention relates to N-substituted 4-amino-  
pteridines of the following general formula, a process  
for their preparation and their use for the prevention  
10 and treatment of diseases caused by a disturbed nitric  
oxide balance.



15 Nitric oxide (NO) is a ubiquitous bearer of  
physiological and pathophysiological functions  
(S. Moncada et al. *Pharmacol. Rev.* **43** (1991), 109-142).  
It has a relaxant effect on the smooth muscles of  
vessels and, in this way, is crucially involved in the  
20 regulation of blood pressure and the proliferation of  
vessel wall cells; it controls, via inhibition of  
platelet aggregation, the coagulation of blood and is  
involved as neuromodulator in the brain and spinal  
cord. NO likewise functions as messenger in the NANC  
25 nerves of the peripheral nervous system. The cytotoxic  
effect of NO is utilized by macrophages and a large  
number of other cells for defence against infections  
but also plays a part in the inflammatory reaction and  
autoimmune reaction.

30


Endogenous NO is produced with the aid of three  
different NO synthase isoenzymes from arginine  
(Kershaw, *Ann. Rep. Med. Chem.* **27** (1992) 69). All the  
isoenzymes require NADPH, flavin adenine dinucleotide,

flavin mononucleotide and tetrahydrobiopterin as cofactors. They differ in their localization in the body, in their regulation by  $\text{Ca}^{2+}$ /calmodulin and in their inducibility by endotoxins and cytokines.


5 Constitutive, calcium-dependent NO synthases are found, for example, in the endothelium (type III) and in the brain (type I) and are there involved in the regulation of blood pressure and coagulation and in conduction processes. The cytokine-inducible, calcium-independent  
10 isoform (type II) occurs in macrophages, smooth muscle cells and hepatocytes. It is able to produce relatively large amounts of NO over a long period and is thought to be responsible for inflammatory and autoimmune processes and the cytotoxic activity of macrophages.

15 A disturbed NO balance results in serious disorders and damage. Thus, excessive production of NO in septic or hemorrhagic shock leads to massive pathological falls in blood pressure. Excessive NO production is involved,  
20 for example, in the development of autoimmune diseases such as type 1 diabetes, and of atherosclerosis and is partly responsible for the glutamate-induced neurotoxicity following cerebral ischemia. High NO concentrations may in addition lead, through  
25 deamination of cytosine, to DNA damage and cancer. Selective inhibition of the NO synthases involved in the particular pathological states is therefore for the treatment or prevention of said diseases.

30 Only a few representatives of N-substituted 4-amino-pterins have been disclosed in the chemical literature to date. All these representatives contain either a substituent differing from hydrogen in the 7 position of the pterin framework or an aminobenzoylglutamate  
35 residue analogous to folic acid in the 6 position of the pterin framework (see formulae (a) and (b) below for the pterin framework).



(a)



(b)

Extremely little information is available about the pharmacological effect of N-substituted 4-aminopterins:  
5 Dewey et al. (Biochem. Pharmacol. 23 (1974) 773) and Weinstock et al. (J. Med. Chem. 11 (1968) 573) report a potential diuretic effect of 2,7-diamino-4-methylamino-6-phenylpteridine, Roth et al. (J. Am. Chem. Soc. 73 (1951) 1914) determined the antagonistic effect of  
10 various folic acid-analogous (2-amino-4-alkylamino-pteridin-6-ylmethyl)aminobenzoylglutamates on *S. faecalis* R. The effect of these derivatives, which is characterized by the authors as "weak", is likely to be attributable to a large extent to the presence of the  
15 aminobenzoylglutamate, which is typical of such agents, in the 6 position of the pteridine.

There has likewise to date been only little discussion of the use of pterin analogues for inhibiting NO  
20 synthase (NOS) in the literature. The majority of published pharmacological approaches to NOS inhibition are based on a competitive effect on the substrate binding site of the enzyme for L-arginine via substrate analogues (see, for example, E.S. Furfine et al. J. Biol. Chem. 269 (1994) 26677).

Further potential NO synthase inhibitors which have been discussed in the literature are N-iminoethyl-ornithine (Mc Call et al., Br. J. Pharmacol. 102 (1991)  
30 234), aminoguanidine (T.P. Misko et al., Eur. J. Pharmacol., 233 (1993) 119, EP547588-A1) and 7-nitro-indazole (P.K. Moore et al., Br. J. Pharmacol. 108 (1993) 296).

The effect of simple 6R-5,6,7,8-tetrahydrobiopterin analogues (BH<sub>4</sub> analogues) on NO production has been investigated by Stuehr et al. (J. Biol. Chem. 264 (1989) 20496), Giovanelli et al. (Proc. Natl. Acad. Sci. 88 (1991) 7091), Mülsch and Busse (J. Cardiovasc. Pharmacol. 17 (1991) S52), Sakai et al. (Mol. Pharmacol. 43 (1992) 6), Werner et al. (FEBS Letters 305 (1992) 160), Wachter et al. (Biochem. J. 289 (1993) 357) and by Hevel and Marletta (Biochemistry 31 (1992) 7160). According to these, 6S-BH<sub>4</sub>, 7-R/S-BH<sub>4</sub>, 6-methyl-5,6,7,8-tetrahydropterin and dihydrobiopterin are able partly to replace the natural cofactor. Biopterin, 6,7-dimethyl-5,6,7,8-tetrahydropterin, tetrahydrofolic acid, dihydrofolic acid, folic acid, tetrahydro-neopterin, dihydroneopterin, neopterin, methotrexate, pterin, 6-hydroxymethylpterin, xanthopterin and isoxanthopterin showed no significant effects. Only with 5-deaza-6-methyl-5,6,7,8-tetrahydropterin was it possible to achieve a weak inhibition of NO synthase. Overfeld et al. (Br. J. Pharmacol., 107 (1992) 1008) observed inhibition of NO production in intact rat alveolar macrophages by BH<sub>4</sub> and sepiapterin, which is presumably based on a feedback mechanism. Pterin-6-carboxylic acid showed no effect in these tests.

Bömmel et al. (J. Biol. Chem. 273 (1998) 33142 and Portland Press Proc. 15 (1998) 57) used pterins and photolabile pterin derivatives for characterizing the tetrahydrobiopterin binding site of NO synthase.

The use of pteridinones for inhibiting NO synthase is disclosed in WO 9414780. EP 0,760,818 and EP 0,760,664 describe the use of a number of differently substituted pteridines and tetrahydropteridines for inhibiting NO synthase. The pterins and pteridines described therein are, however, still in need of improvement in relation to some properties such as activity, selectivity for particularly NO synthase isoforms and solubility.


Pfeiffer et al. (Biochem. J. 328 (1997) 349) describe 4-aminobiopterin as inhibitor of NO synthase (Biochem. J., 328 (1997) 349). These compounds have, inter alia,  
5 a free amino group in the 4 position and a side chain in the 6 position which is unaltered compared with the natural cofactor. Recently solved X-ray structures (B.R. Crane et al., Science 279 (1998) 2121) show interactions of these compounds with NO synthase.

10

It has now been found, surprisingly, that, in particular, pteridines whose amino group in the 4 position is substantially blocked by substituents, preferably by alkylation or dialkylation, and which  
15 have in the 6 position a predominantly lipophilic group are potent inhibitors of NO synthase and, as such, can be used for the treatment of diseases associated with an elevated NO level.

20 The pterins of the general formula I represent, by comparison with the pterins disclosed in EP 0 760 818 and EP 0 760 664, a considerable and, in every respect, surprising advance especially in relation to the NO synthase-inhibiting effect, isoform selectivity and the  
25 sustained improvement in the solubility properties.

The present invention relates to compounds of the general formula I




(I)

30


where



A is a bridge of the form



or



- 5 R<sup>1</sup> is hydrogen, (C<sub>1</sub>-C<sub>10</sub>)-alkyl, aryl or (C<sub>1</sub>-C<sub>3</sub>)-alkylaryl, where the alkyl radicals may be substituted by one or more substituents R<sup>6</sup>,
- 10 R<sup>2</sup> has, independently of R<sup>1</sup>, one of the meanings of R<sup>1</sup> but may not be hydrogen,
- 15 R<sup>1</sup> and R<sup>2</sup> may, together with the nitrogen atom bearing them, form a 3-8-membered ring which may optionally contain 0, 1 or 2 further heteroatoms from the series N, O, S and which is optionally substituted by one or more R<sup>6</sup> radicals,
- 20 R<sup>3</sup> is hydrogen, -CO-(C<sub>1</sub>-C<sub>7</sub>)-alkyl, -CO-(C<sub>1</sub>-C<sub>3</sub>)-alkylaryl or -CO-aryl,
- 25 R<sup>4</sup> is (C<sub>1</sub>-C<sub>10</sub>)-alkyl, aryl or (C<sub>1</sub>-C<sub>3</sub>)-alkylaryl, -CO-O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CO-O-aryl, -CO-(C<sub>1</sub>-C<sub>5</sub>)-alkyl or -CO-aryl, where the alkyl radicals may be substituted by one or more substituents R<sup>7</sup>,
- 30 R<sup>5</sup> has, independently of R<sup>3</sup>, one of the meanings of R<sup>3</sup>,
- R<sup>6</sup> is -F, -OH, -O-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, -O-phenyl, -O-CO-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, -O-CO-aryl, -NR<sup>8</sup>R<sup>9</sup>, oxo, phenyl, -CO-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CF<sub>3</sub>, -CN, -CONR<sup>8</sup>R<sup>9</sup>, -COOH, -CO-O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CO-O-aryl, -S(O)<sub>n</sub>-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -SO<sub>2</sub>-NR<sup>8</sup>R<sup>9</sup>,

R<sup>7</sup> has, independently of R<sup>6</sup>, one of the meanings of R<sup>6</sup>,

R<sup>8</sup> is hydrogen or (C<sub>1</sub>-C<sub>5</sub>)-alkyl,

5

R<sup>9</sup> is hydrogen, (C<sub>1</sub>-C<sub>5</sub>)-alkyl or phenyl,

aryl is phenyl, naphtyl or heteroaryl, all of which may be substituted by one or more identical or different substituents from the series halogen, (C<sub>1</sub>-C<sub>5</sub>)-alkyl, phenyl, -OH, -O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy, -N<sup>8</sup>R<sup>9</sup>, -NO<sub>2</sub>, -CO-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CF<sub>3</sub>, -CN, -CONR<sup>8</sup>R<sup>9</sup>, -COOH, -CO-O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -S(O)<sub>n</sub>-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -SO<sub>2</sub>-NR<sup>8</sup>R<sup>9</sup>,

15

heteroaryl is a 5- to 7-membered unsaturated heterocycle which contains one or more heteroatoms from the series O, N, S,

20 n is 0, 1 or 2,

in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and their physiologically tolerated salts, hydrates and esters.

25

If groups or substituents occur more than once in the compounds of the formula I, they may all, independently of one another, have the stated meanings and may in each case be identical or different.

30

Alkyl radicals may be straight-chain or branched. This also applies if they are present in other groups, for example in alkoxy groups, alkoxycarbonyl groups or in amino groups, or if they are substituted.

35

Examples of alkyl groups are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, the n isomers of these radicals, isopropyl, isobutyl,

isopentyl, sec-butyl, tert-butyl, neopentyl, 3,3-dimethylbutyl. The term alkyl in this case is also understood expressly to mean unsaturated alkyl radicals, i.e. alkyl radicals which contain one or more  
5 double bonds and/or one or more triple bonds, i.e. alkenyl radicals and alkynyl radicals. Examples of such radicals are the vinyl radical, the 2-propenyl radical (allyl radical), the 2-butenyl radical and the 2-methyl-2-propenyl radical, the ethynyl radical, the 2-propynyl radical (propargyl radical) or the 3-butenyl  
10 radical. Moreover, the term alkyl in this case is also understood expressly to mean radicals in which a cyclic system is formed by an internal ring closure, the term alkyl thus also encompasses saturated and partially unsaturated cycloalkyl radicals and cycloalkyl alkyl  
15 radicals (alkyl substituted by cycloalkyl such as, for example, cyclohexylmethyl. Examples of such cycloalkyl radicals are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, all of which may also be substituted for example by one or more  
20 identical or different (C<sub>1</sub>-C<sub>4</sub>)-alkyl radicals, in particular by methyl. Examples of such substituted cycloalkyl radicals are 4-methylcyclohexyl or 2,3-dimethylcyclopentyl.

25 Examples of heteroaryls from which the radicals occurring in compounds of the formula I may be derived are pyrrole, furan, thiophene, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, 1,3-oxazole, 1,2-oxazole, 1,3-thiazole, 1,2-thiazole, tetrazole,  
30 pyridine, pyridazine, pyrimidine, pyrazine, pyran, thiopyran, 1,4-dioxin, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,4,5-tetrazine, azepine, 1,2-diazepine,  
35 1,3-diazepine, 1,4-diazepine, 1,3-oxazepine or 1,3-thiazepine.

The radicals derived from the heterocycles may be bonded via any suitable carbon atom. Nitrogen heterocycles which have a hydrogen atom (or a substituent) on a ring nitrogen atom, for example  
5 pyrrole, imidazole, etc, may also be bonded via a ring nitrogen atom, especially if the relevant nitrogen heterocycle is bonded to a carbon atom. A thienyl radical may, for example, be in the form of a 2-thienyl radical or 3-thienyl radical, a furan radical in the  
10 form of a 2-furyl radical or 3-furyl radical, a pyridyl radical in the form of a 2-pyridyl radical, 3-pyridyl radical or 4-pyridyl radical.

Halogen is fluorine, chlorine, bromine or iodine,  
15 preferably fluorine or chlorine.

$R^1$  is preferably hydrogen,  $(C_2-C_4)$ -alkyl which may be substituted by one or more substituents  $R^6$ , or  $(C_1-C_2)$ -alkylaryl, and  $R^1$  is particularly  
20 preferably arylmethyl

$R^2$  is preferably  $(C_2-C_4)$ -alkyl which may be substituted by one or more substituents  $R^6$ , or  $(C_1-C_2)$ -alkylaryl, and  $R^2$  is particularly  
25 preferably arylmethyl

in addition,  $R^1$  and  $R^2$  preferably form, together with the nitrogen atom bearing them, a 5-7-membered ring which preferably contains no or only  
30 one other heteroatom from the series N, O, S. Very particularly preferred rings of this type are pyrrolidine, piperidine, morpholine, dimethylmorpholine, thiomorpholine or N- $(C_1-C_2)$ -alkylpiperazine, where these rings themselves may also be  
35 substituted, for example by -OH, -O- $(C_1-C_3)$ -alkyl, -NR<sup>8</sup>R<sup>9</sup> or -COOH.

R<sup>3</sup> is preferably hydrogen, CO-(C<sub>1</sub>-C<sub>3</sub>)-alkyl or CO-aryl, and R<sup>3</sup> is very particularly preferably hydrogen.

5 R<sup>4</sup> is preferably aryl, (C<sub>1</sub>-C<sub>5</sub>)-alkyl which may be substituted by one or more substituents R<sup>7</sup>, or -CO-O-aryl. Particularly preferred R<sup>4</sup> radicals are aryl and 1,2-dihydroxypropyl.

10 R<sup>5</sup> is preferably hydrogen.

R<sup>6</sup> is preferably -OH, -O-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, -NR<sup>8</sup>R<sup>9</sup> or -COOH.

15 R<sup>7</sup> is preferably -OH, -O-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, phenoxy, oxo, particularly preferably -OH, decyloxy and phenoxy.

20 aryl is preferably phenyl, thiophenyl, furyl and pyridyl, and phenyl is particularly preferred, all of which can be substituted as described. Preferred substituents are (C<sub>1</sub>-C<sub>3</sub>)-alkyl, halogen and (C<sub>1</sub>-C<sub>3</sub>)-alkyloxy and (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy. The preferred number of substituents on aryl radicals  
25 is 0, 1 or 2; phenyl substituents are preferably in the meta or para position, and in the case of two substituents in the 3 and 4 positions.

30 n is preferably 0 and 2

Concerning so-called structure-activity relations, it must be stated that in this connection in particular the 4 and the 6 positions of the pterin framework appear to be important. In the case of  
35 tetrahydropterins (compare formula (b)), for example large-volume substituents in the 6 position such as, for example, substituted phenyl, increase the activity of the agents. In the case of aromatic structures

(compare formula (a)), an increase in activity is observed preferentially when the amino substituent in the 4 position is dialkylated or diaralkylated and the 6 position is arylated.

5

The invention encompasses all possible enantiomers and diastereomers of the compounds of the general formula I, as well as mixtures of two or more stereoisomeric forms, for example mixtures of enantiomers and/or  
10 diastereomers, in all ratios.

The invention thus encompasses enantiomers in enantiopure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and  
15 in the form of mixtures of the two enantiomers in all ratios. If a cis/trans isomerism is present, both the cis form and the trans form and mixtures of these forms in all ratios are encompassed by the invention. Individual stereoisomers can, if desired, be prepared  
20 by fractionating a mixture by conventional methods, for example by chromatography or crystallization, by use of stereochemically pure starting materials in the synthesis or by stereoselective synthesis. A separation of stereoisomers may, where appropriate, be preceded by  
25 a derivatization. The separation of the mixture of stereoisomers can take place at the stage of compounds of the formula I or at the stage of an intermediate during the synthesis. If mobile hydrogen atoms are present, the present invention also encompasses all  
30 tautomeric forms of the compounds of the formula I.

The invention also encompasses the corresponding physiologically or toxicologically acceptable salts, in particular the pharmaceutically usable salts. Thus, the  
35 compounds of the formula I which contain acidic groups may, for example, be in the form of alkali metal salts, alkaline earth metal salts or of ammonium salts and these groups can be used according to the invention.

Examples of such salts are sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino  
5 acids.


Compounds of the formula I which contain one or more basic, that is protonatable, groups may be in the form of their acid addition salts with physiologically tolerated inorganic or organic acids and used according  
10 to the invention, for example as salts with hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid,  
15 salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfamic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric  
20 acid, adipic acid etc.

If the compounds of the formula I contain both acidic and basic groups in the molecule, the invention also includes inner salts or betaines (zwitterions) in addition to the salt forms described.

25 Salts can be obtained from compounds of the formula I by conventional processes known to the skilled worker, for example by combining with an organic or inorganic acid or base in a solvent or dispersant, or else by anion exchange or cation exchange from other salts. The  
30 present invention further encompasses all solvates of compounds of the formula I, for example hydrates or adducts with alcohols, and derivatives of the compounds of the formula I such as, for example, esters, and prodrugs and active metabolites.

35

Compounds according to the invention of the general formula I can be obtained as shown in the following synthesis scheme



The scheme is explained in detail below:

5

To synthesize compounds of the general formula I, 2,6-diamino-4-chloro-5-p-chlorophenylazopyrimidine (II) as pure substance or in a solvent such as, for example, DMF, toluene or tetrahydrofuran is reacted with a 2-20-fold excess of an amine of the general formula  $\text{HNR}^1\text{R}^2$  (III) at a temperature which is preferably between room temperature (RT) and the boiling point of the solvent.

10



Alternatively, the reaction can also be carried out with an equimolar amount of the amine in the presence of an auxiliary base such as, for example, triethylamine or Hünig base.

5

The resulting 2,6-diamino-4-(subst. amino)-5-p-chloro-phenylazopyrimidines (IV) are hydrogenated in a solvent such as, for example, methanol, ethanol or water, preferably in the presence of an acid such as, for example, HCl or acetic acid, or in the presence of a base such as, for example, ammonia, with the aid of a catalyst such as, for example, Raney nickel, platinum dioxide or palladium on carbon under a pressure of between 1 and 200 atm of hydrogen.

15

The 2,5,6-triamino-4-(subst. amino)pyrimidines (V) obtained in this way are then mixed in a solvent such as, for example, methanol, ethanol, DMF or water with the particular glyoxal monoxime (VI) containing the radical  $R^4$ , and this mixture is stirred until conversion is complete at a temperature which is between RT and the boiling point of the solvent employed. After cooling, the suspension or solution is made basic with a base such as, for example, ammonia, and the precipitate which has separated out is filtered off with suction, washed with water and dried.

25

A solution of the resulting pteridine is hydrogenated in a solvent such as THF, methanol or ethanol with the assistance of a catalyst such as, for example, Raney nickel, platinum dioxide or palladium on carbon under a pressure of between 1 and 200 atm of hydrogen.

30

Further derivatization to introduce the substituents  $R^3$  and/or  $R^4$  can be carried out by standard processes for acylations which are known to the skilled worker.

35

The abovementioned reactions for preparing 4-amino-pteridine derivatives are described in principle, for example, in WO-A-97/21711.

- 5 The present invention likewise relates to the abovementioned processes for preparing compounds of the formula I.

10 Diseases which are produced by an elevated NO level and which thus can be treated according to the invention with compounds of the general formula I or which can be prevented using the latter are, in particular, pathological falls in blood pressure like those occurring in septic or hemorrhagic shock, in tumor  
15 therapy with cytokines or in cirrhosis of the liver, or autoimmune diseases such as type I diabetes, and atherosclerosis. In addition inflammatory diseases such as rheumatoid arthritis and, in particular, ulcerative colitis, and insulin-dependent diabetes mellitus and  
20 transplant rejection reactions.

The following disorders are also associated with an increased production of nitric oxide and can be treated according to the invention. In the cardiovascular  
25 system these are atherosclerosis, post-ischaemic reperfusion damage, myocarditis based on coxsackie virus infection and cardiomyopathy; in the central nervous system types of neuritis, encephalomyelitis, viral neurodegenerative disorders, Alzheimer's disease,  
30 hyperalgesia, epilepsy and migraine; in the renal system acute renal failure and glomerulonephritis.

In addition, areas of application of compounds of the general formula I are also treatments in the region of  
35 the stomach and of the uterus/placenta and influencing the motility of sperm.

Compounds of the formula I and their physiologically tolerated salts, hydrates, esters and adducts can thus be used in animals, preferably in mammals, and in particular in humans, as pharmaceuticals on their own,  
5 or in mixtures with one another or together with other agents. The present invention therefore also relates in particular to the use of compounds of the formula I and their physiologically tolerated salts, hydrates and esters for producing a medicament for the therapy or  
10 prophylaxis of the aforementioned pathological states, and to the use for producing a medicament for lowering or normalizing an NO level.

The invention likewise relates to the use of the  
15 compounds of the formula I and their physiologically tolerated salts, hydrates and esters for inhibiting NO synthase, to their use for the therapy or prophylaxis of the aforementioned pathological states and to their use for normalizing a disturbed NO balance.

20 Likewise encompassed are pharmaceuticals which comprise the compounds of the formula I, their physiologically tolerated salts, esters and hydrates and esters on their own, in mixtures with one another or together  
25 with other agents in addition to conventional excipients and additives.

Examples of such other therapeutically active substances are:  $\beta$ -receptor blockers such as, for  
30 example, propranolol, pindolol, metoprolol; vasodilators such as, for example, carbocromen; sedatives such as, for example, barbituric acid derivatives, 1,4-benzodiazepines and meprobamate; diuretics such as, for example, clororthiazide; cardiotonic agents such as,  
35 for example, digitalis products; agents which lower blood pressure, such as, for example, hydralazine, dihydralazine, ACE inhibitors, prazosin, clonidine, rauwolfia alkaloids; agents which lower the fatty acid

level in the blood, such as, for example, bezafibrate, fenofibrate; agents for thrombosis prophylaxis such as, for example, phenprocoumon; antiinflammatory substances such as, for example, corticosteroids, salicylates, or  
5 propionic acid derivatives such as, for example, ibuprofen; antibiotics such as, for example, penicillins or cephalosporins; NO donors such as, for example, organic nitrates or sydnone imines.

10 Pharmaceuticals of the present invention can be administered orally, for example in the form of pills, tablets, film-coated tablets, sugar-coated tablets, granules, hard and soft gelatin capsules, aqueous,  
15 alcoholic or oily solutions, syrups, emulsions or suspensions, or rectally, for example in the form of suppositories. The administration can, however, take place parenterally, for example subcutaneously, intramuscularly or intravenously in the form of injection solutions or infusion solutions. Further  
20 suitable administration forms are, for example, percutaneous or topical administration, for example in the form of ointments, tinctures, sprays or transdermal therapeutic systems, or inhalational administration in the form of nasal sprays or aerosol mixtures, or, for  
25 example, microcapsules, implants or rods. The preferred mode of administration depends, for example, on the disease to be treated and its severity.

The medicaments according to the invention can be  
30 produced by the standard processes known for producing pharmaceutical products.

For this purpose, one or more compounds of the formula I and/or their physiologically tolerated salts, esters  
35 and hydrates are converted together with one or more solid or liquid pharmaceutical carriers and/or additives or excipients and, if desired, in combination with other active pharmaceutical ingredients with

therapeutic or prophylactic action into a suitable administration form or dosage form, which can then be used as pharmaceutical in human medicine or veterinary medicine. The pharmaceutical products comprise a therapeutically or prophylactically effective dose of the compounds of the formula I and/or their physiologically tolerated salts, esters and hydrates, which normally amounts to from 0.5 to 90% by weight of the pharmaceutical product.

To produce, for example, pills, tablets, sugar-coated tablets and hard gelatin capsules it is possible to use lactose, starch, for example corn starch or starch derivatives, talc, stearic acid or salts thereof etc. Carriers for soft gelatin capsules and suppositories are for example fats, waxes, semisolid and liquid polyols, natural or hydrogenated oils etc. Examples of carriers suitable for producing solutions, for example injection solutions, or emulsions or syrups are water, physiological saline, alcohols such as ethanol, glycerol, polyols, sucrose, invert sugar, glucose, mannitol, vegetable oils etc. The compounds of the formula I and their physiologically tolerated salts, esters and hydrates may also be lyophilized, and the resulting lyophilizates can be used, for example, for producing products for injection or products for infusion. Examples of carriers suitable for microcapsules, implants or rods are copolymers of glycolic acid and lactic acid.

The pharmaceutical products may besides the active ingredients and carriers also comprise conventional additives, for example fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavoring or aromatizing agents, thickeners, diluents, buffer substances, also solvents or solubilizers or

means to achieve a depot effect, salts to alter the osmotic pressure, coating agents or antioxidants.

5 The dosage of the active ingredient of the formula I to be administered, and/or of a physiologically tolerated salt, ester or hydrate thereof depends on the individual case and should be adapted to the individual circumstances for an optimal effect in the conventional way. Thus, it depends on the nature and severity of the  
10 disease to be treated and on the sex, age, weight and individual response of the human or animal to be treated, on the potency and duration of action of the compounds employed, on whether the therapy is acute or chronic or the aim is prophylaxis, or on whether other  
15 active ingredients are administered in addition to compounds of the formula I. In general, a daily dose of about 0.01 to 100 mg/kg, preferably 0.1 to 10 mg/kg, in particular 0.3 to 5 mg/kg (in each case mg per kg of body weight) is appropriate on administration to an  
20 adult weighing about 75 kg to achieve the desired effect. The daily dose may be administered in a single dose or, especially on administration of larger amounts, be divided into a plurality of, for example two, three or four, single doses. It may, depending on  
25 the individual characteristics, be necessary where appropriate to deviate upward or downward from the stated daily dose. Pharmaceutical products normally contain 0.2 to 500 mg, preferably 1 to 200 mg, of active ingredient of the formula I and/or its  
30 physiologically tolerated salts.

The compounds of the formula I inhibit the various isoforms of NO synthase mainly through binding in the tetrahydrobiopterin binding cavity of the enzyme.  
35 Because of this property, they may be employed not only as active pharmaceutical ingredients in human medicine and veterinary medicine but also as scientific tool or as aid for biochemical investigations in which such an

inhibition of NO synthase is intended, and for diagnostic purposes, for example in the in vitro diagnosis of cell samples or tissue samples. The compounds of the formula I and their salts, esters or hydrates may also be used as intermediates for preparing other active pharmaceutical ingredients.

### Examples

The following preparation methods and examples illustrate the invention without restricting it:

#### **2,6-Diamino-4-chloro-5-p-chlorophenylazopyrimidine**

A solution of p-chloroaniline (25.5 g, 0.2 moles) in 6 N HCl (100 mL) was cooled to 0-5°C and then a solution of NaNO<sub>2</sub> (13.8 g, 0.2 moles) in water (40 ml) was added dropwise with stirring. After completion of the addition, the solution was stirred for a further 15 min, and the progress of the reaction was checked with the aid of iodine/starch paper (blue coloration). The excess HNO<sub>2</sub> was destroyed by adding urea (5 g). The diazonium salt solution was poured into a solution of 2,6-diamino-4-chloropyrimidine (26.0 g, 0.18 moles) in water (500 mL) and stirred for 30 min. Potassium acetate (70 g) was then added, and the mixture was stirred at room temperature for 16 hours. The precipitated product was filtered off with suction, washed with H<sub>2</sub>O and dried over P<sub>4</sub>O<sub>10</sub> in a desiccator in vacuo. Yield: 44.0 g (81%) of yellow solids. Recrystallization from DMF/H<sub>2</sub>O. m.p.: 268°C.

#### **2,6-Diamino-4-alkylamino-5-p-chlorophenylazopyrimidines**

General procedure:

A solution of 2,6-diamino-4-chloro-5-p-chlorophenylazopyrimidine (5.0 g, 16.6 mmol) and 10 g of the amine in DMF (50 mL) was stirred in an oil bath at 70°C for

5 hours. Addition of water (50 mL) was followed by cooling and filtering off the precipitate with suction, washing with water, drying and recrystallizing from EtOH or acetone/water.

5

The following were obtained in this way:

- 1.) 2,6-diamino-4-diethylamino-5-p-chlorophenylazo-  
pyrimidine, m.p.: 145-148°C
- 10 2.) 2,6-diamino-4-dibenzylamino-5-p-chlorophenylazo-  
pyrimidine, m.p.: 185-186°C.
- 3.) 2,6-diamino-4-(morpholin-4-yl)-5-p-chlorophenyl-  
15 azopyrimidine, m.p.: 219-221°C.
- 4.) 2,6-diamino-4-(piperidin-1-yl)-5-p-chlorophenyl-  
azopyrimidine, m.p.: 199-201°C.
- 20 5.) 2,6-diamino-4-(4-methylpiperazin-1-yl)-5-p-chloro-  
phenylazopyrimidine, m.p.: 218-220°C.

#### **2,5,6-Triamino-4-alkylaminopyrimidines (hydrochlorides)**

25 General procedure:

A solution of 10 mmol of the 2,6-diamino-4-alkylamino-5-p-chlorophenylazopyrimidine in methanol (70 mL) and conc. ammonia (10 mL) was reduced in a shaking  
30 apparatus in the presence of the catalyst Raney nickel (3.5 g) under an H<sub>2</sub> atmosphere for 2 days. The catalyst was filtered off under an argon atmosphere and the filtrate was evaporated to dryness in vacuo. The residue was treated with ether to remove the p-chloro-  
35 aniline, and the remaining solid was stirred with methanolic HCl (10%, 50 mL) overnight. The dihydrochloride salt was filtered off with suction and dried over KOH in a desiccator in vacuo.



The following were obtained in this way:

- 5        6.) 2,5,6-triamino-4-diethylaminopyrimidine    dihydro-  
         chloride, m.p.: 138-142°C
- 7.) 2,5,6-triamino-4-dibenzylaminopyrimidine    dihydro-  
         chloride, m.p.: 165-167°C
- 10    8.) 2,5,6-triamino-4-(morpholin-4-yl)-pyrimidine  
         dihydrochloride, m.p.: 215-218°C (decomposition)
- 9.) 2,5,6-triamino-4-(piperidin-1-yl)-pyrimidine  
         dihydrochloride, m.p.: 238-242°C
- 15       10.) 2,5,6-triamino-4-(4-methylpiperazin-1-yl)-  
         pyrimidine trihydrochloride,    m.p.:    226-230°C  
         (decomposition)

20    **2-Amino-4-alkylamino-6-(R<sup>4</sup>)-pteridines**

General procedure:

25    A solution of the arylglyoxal monoxime (7.5 mmol)  
     containing the radical R<sup>4</sup> in MeOH (10 mL) was added  
     dropwise to a boiling solution of 2,5,6-triamino-4-  
     alkylaminopyrimidine dihydrochloride salt (5 mmol) in  
     MeOH (20 mL), and this mixture was boiled under reflux  
     for 3 hours. After cooling, the suspension or solution  
30    was adjusted to pH 9-10 with conc. ammonia, and the  
     precipitate which separated out was filtered off with  
     suction, washed with water and dried. The crude product  
     was recrystallized from EtOH and DMF/H<sub>2</sub>O.

35    The following were obtained in this way:

- 11.) 2-amino-4-(dimethylamino)-6-phenylpteridine, m.p.:  
         247-250°C

- 12.) 2-amino-4-(dimethylamino)-6-(4-methylphenyl)-  
pteridine, m.p.: 251-256°C
- 5 13.) 2-amino-4-(dimethylamino)-6-(4-methoxyphenyl)-  
pteridine, m.p.: 280-284°C (decomposition)
- 14.) 2-amino-4-(dimethylamino)-6-methoxymethyl-  
pteridine, m.p.: 237-239°C
- 10 15.) 2-amino-4-(diethylamino)-6-phenylpteridine  
hydrate, m.p.: 203-205°C
- 15 16.) 2-amino-4-(diethylamino)-6-(4-chlorophenyl)-  
pteridine dihydrate, m.p.: 250-254°C  
(decomposition)
- 17.) 2-amino-4-(diethylamino)-6-(4-methoxyphenyl)-  
pteridine hydrate, m.p.: 220-222°C
- 20 18.) 2-amino-4-(diethylamino)-6-(3,4-dimethoxyphenyl)-  
pteridine hydrate, m.p.: 182-185°C
- 19.) 2-amino-4-(dibenzylamino)-6-phenylpteridine  
25 dihydrate, m.p.: 225-227°C
- 20.) 2-amino-4-(dibenzylamino)-6-(4-chlorophenyl)-  
pteridine dihydrate, m.p.: 250-253°C
- 30 21.) 2-amino-4-(dibenzylamino)-6-(4-methoxyphenyl)-  
pteridine, m.p.: 245-247°C
- 22.) 2-amino-4-(dibenzylamino)-6-(3,4-dimethoxyphenyl)-  
pteridine hemihydrate, m.p.: 200-201°C
- 35 23.) 2-amino-4-(di-n-propylamino)-6-phenylpteridine  
trihydrate, m.p.: 177-178°C

- 24.) 2-amino-4-(di-n-propylamino)-6-(4-chlorophenyl)-  
pteridine trihydrate, m.p.: 189-192°C  
(decomposition)
- 5 25.) 2-amino-4-(di-n-propylamino)-6-(4-methoxyphenyl)-  
pteridine hydrate, m.p.: 207-210°C (decomposition)
- 26.) 2-amino-4-(di-n-propylamino)-6-(3,4-dimethoxy-  
phenyl)pteridine hydrate, m.p.: 158-160°C
- 10 27.) 2-amino-4-(morpholin-4-yl)-6-phenylpteridine  
hydrate, m.p.: 224-227°C (decomposition)
- 28.) 2-amino-4-(morpholin-4-yl)-6-(4-chlorophenyl)-  
15 pteridine hydrochloride hydrate, m.p.: 252-254°C  
(decomposition)
- 29.) 2-amino-4-(morpholin-4-yl)-6-(4-methoxyphenyl)-  
pteridine hydrochloride hydrate, m.p.: 238-240°C  
20 (decomposition)
- 30.) 2-amino-4-(morpholin-4-yl)-6-(3,4-dimethoxy-  
phenyl)pteridine trihydrate, m.p.: 218-220°C  
(decomposition)
- 25 31.) 2-amino-4-(piperidin-1-yl)-6-phenylpteridine  
dihydrate, m.p.: 209-211°C
- 32.) 2-amino-4-(piperidin-1-yl)-6-(4-chlorophenyl)-  
30 pteridine dihydrate, m.p.: 245-247°C  
(decomposition)
- 33.) 2-amino-4-(piperidin-1-yl)-6-(4-methoxyphenyl)-  
pteridine hydrate, m.p.: 211-214°C (decomposition)
- 35 34.) 2-amino-4-(piperidin-1-yl)-6-(3,4-dimethoxy-  
phenyl)pteridine hydrochloride dihydrate, m.p.:  
238-241°C (decomposition)

35.) 2-amino-4-(4-methylpiperazin-1-yl)-6-phenyl-  
pteridine hemihydrate, m.p.: 245-247°C  
(decomposition)

5

36.) 2-amino-4-(4-methylpiperazin-1-yl)-6-(4-chloro-  
phenyl)pteridine hemihydrate, m.p.: 277-279°C  
(decomposition)

10 37.) 2-amino-4-(4-methylpiperazin-1-yl)-6-(4-methoxy-  
phenyl)pteridine hemihydrate, m.p.: 228-230°C  
(decomposition)

15 38.) 2-amino-4-(4-methylpiperazin-1-yl)-6-(3,4-di-  
methoxyphenyl)pteridine dihydrate, m.p.: 148-151°C  
(decomposition)

20 39.) 2-amino-4-(pyrrolidin-1-yl)-6-(4-methoxyphenyl)-  
pteridine dihydrate, m.p.: 243-246°C  
(decomposition)

**2-Amino-4-alkylamino-6-(R<sup>4</sup>)-5,6,7,8-tetrahydro-  
pteridines**

25 General procedure:

A solution of pteridine (3 mmol) to be reduced in THF  
(25 ml) was agitated catalytically with PtO<sub>2</sub> (0.10 g)/H<sub>2</sub>  
in a shaking apparatus until hydrogen uptake ceased.  
30 The catalyst was filtered off, the filtrate was  
evaporated to dryness, and the residue was treated with  
methanolic HCl with stirring for several hours. The  
crystals which formed were filtered off with suction,  
washed with ether and dried in a desiccator in vacuo.

35

The following were obtained in this way:

- 40.) 2-amino-4-(morpholin-4-yl)-6-(4-methoxyphenyl)-  
5,6,7,8-tetrahydropteridine hydrochloride hemi-  
hydrate, m.p.: 219-222°C
- 5 41.) 2-amino-4-(morpholin-4-yl)-6-(3,4-dimethoxy-  
phenyl)-5,6,7,8-tetrahydropteridine hydrochloride  
hydrate, m.p.: 168°C
- 10 42.) 2-amino-4-(morpholin-4-yl)-6-phenyl-5,6,7,8-tetra-  
hydropteridine dihydrochloride hemihydrate, m.p.:  
200-203°C
- 15 43.) 2-amino-4-(piperidin-1-yl)-6-(4-chlorophenyl)-  
5,6,7,8-tetrahydropteridine trihydrochloride  
hydrate, m.p.: 170°C
- 20 44.) 2-amino-4-(piperidin-1-yl)-6-(4-methoxyphenyl)-  
5,6,7,8-tetrahydropteridine trihydrochloride  
hydrate, m.p.: 218-220°C
- 45.) 2-amino-4-(piperidin-1-yl)-6-phenyl-5,6,7,8-tetra-  
hydropteridine dihydrochloride dihydrate, m.p.:  
178-182°C
- 25 46.) 2-amino-4-(di-n-propylamino)-6-phenyl-5,6,7,8-  
tetrahydropteridine trihydrochloride hydrate,  
m.p.: 115°C
- 30 47.) 2-amino-4-(di-n-propylamino)-6-(4-methoxyphenyl)-  
5,6,7,8-tetrahydropteridine dihydrochloride  
dihydrate, m.p.: 120°C
- 35 48.) 2-amino-4-(diethylamino)-6-(4-chlorophenyl)-  
5,6,7,8-tetrahydropteridine dihydrochloride hemi-  
hydrate, m.p.: 138°C

49.) 2-amino-4-(cyclohexylmethylamino)-6-(4-chloro-phenyl)-5,6,7,8-tetrahydropteridine dihydro-chloride hydrate, m.p.: 160°C

- 5 The inhibition of the activity of purified nitric oxide synthase (NOS) by compounds of the general formula I can be determined as follows.

10 In this activity assay there is quantitative measurement of L-citrulline which is a coproduct of the formation of NO by purified NOS. 3H-radiolabeled L-arginine is employed as substrate of the enzymic reaction and is converted into 3H-Lcitrulline and NO. After completion of the enzyme incubation, the resulting L-citrulline is  
15 removed from unused L-arginine by ion exchange chromatography from the reaction mixture; the 3H activity measured by liquid scintillation then corresponds to the amount of L-citrulline, which is a direct measure of the activity of NOS.

20

The basic medium for carrying out the enzymic reaction is TE buffer (triethanolamine, EDTA, pH 7.0).

25 The final volume of each incubation is 100  $\mu$ l. The reaction mixture is obtained by mixing the following 6 components on ice:

1. "REA mix" (pH 7.0) which contains triethanolamine, calcium chloride, magnesium chloride, EDTA,  
30 L-arginine, calmodulin and flavin adenine dinucleotide (FAD);
2. freshly prepared stock solution of  $\beta$ -nicotinamide adenine dinucleotide phosphate, reduced form (NADPH);
- 35 3. (6R)-5,6,7,8-tetrahydro-L-biopterin dihydro-chloride stock solution ( $\text{BH}_4$ ) or - for experiments without  $\text{BH}_4$  - instead TE buffer;

4. purified NO synthase from pig cerebellum or from pig liver;
5. L-[2,3,4,5-<sup>3</sup>H]-arginine hydrochloride stock solution (1.52.6 TBq/mmol);
- 5 6. substance to be tested.

The final concentrations of the components in the incubation volume of 100  $\mu$ l are:

Triethanolamine 50 mM, EDTA 0.5 mM, CaCl<sub>2</sub> 226  $\mu$ M, MgCl<sub>2</sub>  
10 477  $\mu$ M, L-arginine 50  $\mu$ M, calmodulin 0.5  $\mu$ M, FAD 5  $\mu$ M,  
NADPH 1 mM, BH<sub>4</sub> (if added) 2  $\mu$ M, substance to be tested  
100  $\mu$ M.

After mixing of the components on ice, the reaction  
15 mixture was immediately incubated in a waterbath at  
37°C for 15 minutes. The IC<sub>50</sub> values were determined by  
incubation in the presence of 5 kU/ml catalase for  
45 minutes. After this incubation time, the reaction  
was stopped by addition of 900  $\mu$ l of ice-cold "stop  
20 buffer" (20 mM sodium acetate, 2 mM EDTA, pH 5.5), and  
the mixture (total volume now 1.0 ml) was placed on  
ice. To remove the unreacted 3H-L-arginine, the mixture  
was loaded onto an ion exchange column with 0.8 ml of  
Dowex AG 50 WX-8 (100-200 mesh) which has previously  
25 been washed and equilibrated with 2 ml of stop buffer.  
After loading of the sample, the column was eluted  
twice with 1 ml of water each time. The flow-through of  
the sample and the eluate were collected in  
scintillation vessels and purified (total volume 3 ml).  
30 9 ml of scintillator solution were added to the 3 ml of  
aqueous measurement solution, and the homogeneous  
mixture was measured in a Tricarb 2500 TR (Packard)  
liquid scintillation counter for 1 minute for each  
sample. The activity found with the substance to be  
35 tested has been stated as a percentage of the activity  
of the control. Each substance was tested for an  
antagonistic effect in a concentration of 100  $\mu$ M in the  
presence of 2  $\mu$ M tetrahydrobiopterin, and for an

agonistic effect on NOS in the absence of tetrahydrobiopterin.

5 All incubations were carried out on triplicates. Each experiment was repeated three times with different enzyme preparations. Some results are indicated in the following table.

Example	Remaining activity (% of $V_{\max}$ )	IC <sub>50</sub> (μM)
11	92±11	-
13	13±4	74
15	75±3	-
17	2±0.1	45
19	0±0.05	3
21	0±0.05	5
27	41±8	82
29	5±0.1	34
31	0±0.05	62
33	7±0.2	50
35	83±1	-
37	84±5	-

10 In addition, the relative selectivities of the antipterin inhibitors for the three known human NOS isoforms were measured. This entailed formation of the IC<sub>50</sub> values for NOS-II/NOS-I and NOS-III/NOS-I (compare table 2).

15

The data show that the substances have an increased selectivity for inhibition of NOS-I relative to NOS-II and an increased selectivity relative to NOS-III.




Table II

Substance Example	NOS isoform	Activity (% of control)	IC <sub>50</sub> ( $\mu$ M)	Ratio NOS-II/I	Ratio NOS-III/I
21	NOS-I	27 $\pm$ 1	18.7	21.3	5.3
	NOS-II	81 $\pm$ 6	400 <sup>a</sup>		
	NOS-III	68 $\pm$ 2	100		
45	NOS-I	0 $\pm$ 0	22.0	3.7	0.6
	NOS-II	50 $\pm$ 2	81.5		
	NOS-III	11 $\pm$ 1	14.2		
46	NOS-I	1 $\pm$ 0.1	18.7	10.7	2.9
	NOS-II	68 $\pm$ 1	200 <sup>a</sup>		
	NOS-III	27 $\pm$ 0.2	53.4		
47	NOS-I	0 $\pm$ 0.1	7.4	33.8	8.6
	NOS-II	78 $\pm$ 0.4	250 <sup>a</sup>		
	NOS-III	31 $\pm$ 3	63.6		
48	NOS-I	2 $\pm$ 0	41.5	7.2	1.1
	NOS-II	74 $\pm$ 4	300 <sup>a</sup>		
	NOS-III	27 $\pm$ 1	45.4		
49	NOS-I	0 $\pm$ 0.1	4.9	40.8	7.3
	NOS-II	78 $\pm$ 6	200 <sup>a</sup>		
	NOS-III	18 $\pm$ 1	36		

<sup>a</sup> Enzyme inhibition not complete up to 300 $\mu$ M (IC<sub>50</sub> values extrapolated).


# Patent Claims

1. A compound of the formula I




in which

A is a bridge of the formula



or



$R^1$  is hydrogen,  $(C_1-C_{10})$ -alkyl, aryl or  $(C_1-C_3)$ -alkylaryl, where the alkyl radicals may be substituted by one or more substituents  $R^6$ ,

$R^2$  which has, independently of  $R^1$ , one of the meanings of  $R^1$  but may not be hydrogen,

$R^1$  and  $R^2$  may, together with the nitrogen atom bearing them, form a 3-8-membered ring which may optionally contain 0, 1 or 2 further heteroatoms from the series N, O, S and which is optionally substituted by one or more  $R^6$  radicals,

$R^3$  is hydrogen,  $-CO-(C_1-C_7)$ -alkyl,  $-CO-(C_1-C_3)$ -alkylaryl or  $-CO$ -aryl,

R<sup>4</sup> is (C<sub>1</sub>-C<sub>10</sub>)-alkyl, aryl or (C<sub>1</sub>-C<sub>3</sub>)-alkylaryl, -CO-O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CO-O-aryl, -CO-(C<sub>1</sub>-C<sub>5</sub>)-alkyl or -CO-aryl, where the alkyl radicals may be substituted by one or more substituents R<sup>7</sup>,

R<sup>5</sup> has, independently of R<sup>3</sup>, one of the meanings of R<sup>3</sup>,

R<sup>6</sup> is -F, -OH, -O-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, -O-phenyl, -O-CO-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, -O-CO-aryl, -NR<sup>8</sup>R<sup>9</sup>, oxo, phenyl, -CO-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CF<sub>3</sub>, -CN, -CONR<sup>8</sup>R<sup>9</sup>, -COOH, -CO-O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CO-O-aryl, -S(O)<sub>n</sub>-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -SO<sub>2</sub>-NR<sup>8</sup>R<sup>9</sup>,

R<sup>7</sup> has, independently of R<sup>6</sup>, one of the meanings of R<sup>6</sup>,

R<sup>8</sup> is hydrogen or (C<sub>1</sub>-C<sub>5</sub>)-alkyl,

R<sup>9</sup> is hydrogen, (C<sub>1</sub>-C<sub>5</sub>)-alkyl or phenyl,

aryl is phenyl, naphtyl or heteroaryl, all of which may be substituted by one or more identical or different substituents from the series halogen, (C<sub>1</sub>-C<sub>5</sub>)-alkyl, phenyl, -OH, -O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy, -N<sup>8</sup>R<sup>9</sup>, -NO<sub>2</sub>, -CO-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CF<sub>3</sub>, -CN, -CONR<sup>8</sup>R<sup>9</sup>, -COOH, -CO-O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -S(O)<sub>n</sub>-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -SO<sub>2</sub>-NR<sup>8</sup>R<sup>9</sup>,

heteroaryl is a 5- to 7-membered unsaturated heterocycle which contains one or more heteroatoms from the series O, N, S,

n is 0, 1 or 2,

in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios and its physiologically tolerated salts, hydrates and esters.

5 2. A compound of the formula I as claimed in claim 1, in which

10  $R^1$  is hydrogen,  $(C_2-C_4)$ -alkyl which may be substituted by one or more substituents  $R^6$ , or  $(C_1-C_2)$ -alkylaryl,

15  $R^2$  is  $(C_2-C_4)$ -alkyl which may be substituted by one or more substituents  $R^6$ , or cyclohexylmethyl or  $(C_1-C_2)$ -alkylaryl,

or  $R^1$  and  $R^2$  form, together with the nitrogen atom bearing them, a 5-7-membered ring which optionally contains no or another heteroatom from the series N, O, S,

20  $R^3$  is hydrogen,  $-CO-(C_1-C_3)$ -alkyl or  $-CO$ -aryl,

$R^4$  is aryl,  $(C_1-C_5)$ -alkyl which may be substituted by one or more substituents  $R^7$ , or  $-CO-O$ -aryl,

25  $R^5$  is hydrogen,

$R^6$  is  $-OH$ ,  $-O-(C_1-C_3)$ -alkyl,  $-NR^8R^9$  or  $-COOH$ ,

30  $R^7$  is  $-OH$ ,  $(C_1-C_{10})$ -alkyloxy, phenoxy or oxo,

aryl is phenyl, thiophenyl, furyl or pyridyl, each of which may be substituted by one or more substituents from the series  $(C_1-C_3)$ -alkyl, 35 halogen,  $(C_1-C_3)$ -alkyloxy and  $(C_1-C_2)$ -alkylenedioxy, and

$R^8$  and  $R^9$  have the meanings stated in claim 1,

in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios and its physiologically tolerated salts, hydrates and esters.

5

3. A compound of the formula I as claimed in claim 1 or 2, in which

$R^1$  is arylmethyl and

10

$R^2$  is arylmethyl or cyclohexylmethyl,

or  $R^1$  and  $R^2$  form, together with the nitrogen atom bearing them, a pyrrolidine, piperidine, morpholine, dimethylmorpholine, thiomorpholine, or N-(C<sub>1</sub>-C<sub>2</sub>)-alkylpiperazine ring,

15

$R^3$  is hydrogen,

20  $R^4$  is alkyl or 1,2-dihydroxypropyl,

$R^5$  is hydrogen

$R^6$  is -OH, -O-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, -NR<sup>8</sup>R<sup>9</sup> or -COOH,

25

$R^7$  is -OH, decyloxy and phenoxy,

aryl is phenyl which may be substituted by one or more substituents from the series (C<sub>1</sub>-C<sub>3</sub>)-alkyl, halogen and (C<sub>1</sub>-C<sub>3</sub>)-alkyloxy and (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy, and

30

$R^8$  and  $R^9$  have the meanings stated in claim 1 or 2,

in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios and its physiologically tolerated salts, hydrates and esters.

35

4. A pharmaceutical comprising a compound of the formula I as claimed in one or more of claims 1 to 3 in addition to conventional excipients and additives and, where appropriate, further active ingredients.

5


5. The use of a compound of the formula I as claimed in one or more of claims 1 to 3 for producing a pharmaceutical for the therapy and prophylaxis of strokes, pathological falls in blood pressure, in particular in septic shock and in cancer therapy with cytokines, ulcerative colitis, transplant rejection reactions, nephritis, reperfusion damage, infarct damage, cardiomyopathy, Alzheimer's disease, epilepsy, migraine and neuritis of varying etiology.

15

6. The use of a compound of the formula I as claimed in one or more of claims 1 to 3 as inhibitor of NO synthase.

20 7. The use as claimed in claim 6 for diagnostic purposes.

8. A process for preparing a compound of the formula I as claimed in one or more of claims 1 to 3, by  
25 reacting a compound of the formula II




(II)

with a compound of the formula III


30




to give a compound of the formula IV



and converting the latter by catalytic hydrogenation  
 5 into a compound of the formula V



which is reacted with a compound of the formula VI  
 10




to give a compound of the formula I, which can be  
 converted by suitable derivatization, preferably  
 15 acylation, into the desired compound of the formula I  
 or its physiologically tolerated salts, hydrates,  
 esters and adducts, and in which the substituents have  
 the meanings stated in claims 1 to 3.

Abstract

N-Substituted 4-aminopteridines, a process for their preparation and their use as pharmaceuticals



5

A compound of the formula I



10 in which preferably

A is a bridge of the form



15

$R^1$  and  $R^2$  are, independently of one another, (substituted) alkyl, aryl or aralkyl or together form a heterocycle,

20  $R^3$  is hydrogen, -CO-alkyl or -CO-aryl,

$R^4$  is aryl, -CO-O-aryl or -CO-aryl and

$R^5$  is hydrogen



are potent inhibitors of NO synthase and are suitable as active substances for pharmaceuticals for the prophylaxis and therapy of diseases connected with a disturbed NO balance.